

## PRESS RELEASE

Lyon, January 16, 2023



# Number of shares and voting rights of ADOCIA as of December 31<sup>st</sup>, 2022

6:00pm CET- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, releases its total number of outstanding shares as well as its voting rights as of December 31<sup>st</sup>, 2022.

Month	Date	Total number of outstanding shares	Total number of theoretical voting rights (1)	Total number of exercisable voting rights (2)
December	12/31/2022	8,726,317*	11,546,917	11,517,947

\*including 162,362 new shares resulting from the conversion of 440,000 bonds convertible into shares (OC 1023 & OC1124) issued by the Company on October 26, 2021 and December 1, 2022. The main characteristics are described in the press releases of the days of issue.

(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or "net" voting rights) is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement.

## About Adocia

[Adocia](#) is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on four proprietary technology platforms:

- 1) The BioChaperone<sup>®</sup> technology for the development of new generation insulins and products combining insulins with other classes of hormones;
- 2) AdOral<sup>®</sup>, an oral peptide delivery technology;
- 3) AdoShell<sup>®</sup>, an immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells transplantation;
- 4) AdoGel<sup>®</sup>, a long-acting drug delivery platform.

Adocia holds more than 25 patent families.

Based in Lyon, the company has about 100 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

## Contact

### Adocia

**Gérard Soula**

CEO

[contactinvestisseurs@adocia.com](mailto:contactinvestisseurs@adocia.com)

Tel : +33 4 72 610 610

[www.adocia.com](http://www.adocia.com)

### Ulysse Communication

Adocia Press and Investors Relations

**Pierre-Louis Germain**

[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com) / + 33 (0)6 64 79 97 51

**Margaux Puech Pays d'Alissac**

[mpuech@ulyse-communication.com](mailto:mpuech@ulyse-communication.com) / +33 (0)7 86 16 01 09

**Bruno Arabian**

[barabian@ulyse-communication.com](mailto:barabian@ulyse-communication.com) / +33 (0)6 87 88 47 26



European **Rising Tech**  
LABEL



**ADOCIA**

innovative medicine  
for everyone, everywhere



## Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at [www.adocia.com](http://www.adocia.com)), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic

context, the financial markets and the markets in which Adocia operates.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia's shares in any jurisdiction.